Genfit Overview
Is GNFT undervalued? Intrinsic value estimate stands at $-4.8.
Get informed when a big investor buys or sells
+ Follow$-4.84
Overvalued by 154.1% based on the discounted cash flow analysis.
Genfit (GNFT) currently reports a DCF fair value of $-4.8. Use the charts on this page to explore Genfit's DCF fair value history and peer comparisons.
Genfit's discounted cash flow (DCF) fair value estimate is $-4.8, about 154.1% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.
Start with the current DCF fair value of $-4.8, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Genfit, and consider following GNFT for alerts when major investors trade the stock.
Genfit is classified in the Healthcare sector. On DCF fair value, it currently shows $-4.8. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GNFT with unrelated industries.
